Skip to main content

2019 | Zervixkarzinom | OriginalPaper | Buchkapitel

4. Maligne, nichtepitheliale Tumoren des Corpus uteri (ausschließlich des Karzinosarkoms)

verfasst von : Patrick Imesch, Edgar Petru, Daniel Fink

Erschienen in: Praxisbuch Gynäkologische Onkologie

Verlag: Springer Berlin Heidelberg

Zusammenfassung

In diesem Kapitel werden die eigentlichen Sarkome des Uterus, das Leiomyosarkom, das undifferenzierte Sarkom, das endometriale Stromasarkom sowie das Adenosarkom besprochen. Das Karzinosarkom, auch maligner, gemischter mesenchymaler Tumor oder maligner, gemischter mesodermaler Tumor (MMT) genannt, ist monoklonalen epithelialen Ursprungs, gehört zu den entdifferenzierten Endometriumkarzinomen und wird im Kapitel der Endometriumkarzinome besprochen.
Literatur
Zurück zum Zitat Abeler VM, Nenodovic M (2011) Diagnostic immunohistochemistry in uterine sarcomas: a study of 397 cases. Int J Gynecol Pathol 30(3):236–243 CrossRef Abeler VM, Nenodovic M (2011) Diagnostic immunohistochemistry in uterine sarcomas: a study of 397 cases. Int J Gynecol Pathol 30(3):236–243 CrossRef
Zurück zum Zitat Abu-Rustum NR, Curtin JP, Burt M, Jones WB (1997) Regression of uterine low-grade smooth-muscle tumors metastatic to the lung after oophorectomy. Obstet Gynecol 89:850–852 CrossRef Abu-Rustum NR, Curtin JP, Burt M, Jones WB (1997) Regression of uterine low-grade smooth-muscle tumors metastatic to the lung after oophorectomy. Obstet Gynecol 89:850–852 CrossRef
Zurück zum Zitat Berchuck A, Rubin SC, Hoskins WJ, Saigo PE, Pierce VK, Lewis JL (1988) Treatment of uterine leiomyosarcoma. Obstet Gynecol 71:845–850 PubMed Berchuck A, Rubin SC, Hoskins WJ, Saigo PE, Pierce VK, Lewis JL (1988) Treatment of uterine leiomyosarcoma. Obstet Gynecol 71:845–850 PubMed
Zurück zum Zitat Berchuck A, Rubin SC, Hoskins WJ, Saigo PE, Pierce VK, Lewis JL Jr (1990) Treatment of endometrial stromal tumors. Gynecol Oncol 36:60–65 CrossRef Berchuck A, Rubin SC, Hoskins WJ, Saigo PE, Pierce VK, Lewis JL Jr (1990) Treatment of endometrial stromal tumors. Gynecol Oncol 36:60–65 CrossRef
Zurück zum Zitat Bodner K, Bodner-Adler B, Obermair A et al (2001) Prognostic parameters in endometrial stromal sarcoma: a clinicopathologic study in 31 patients. Gynecol Oncol 81:160–165 CrossRef Bodner K, Bodner-Adler B, Obermair A et al (2001) Prognostic parameters in endometrial stromal sarcoma: a clinicopathologic study in 31 patients. Gynecol Oncol 81:160–165 CrossRef
Zurück zum Zitat Brooks SE, Zhan M, Cote T, Baquet CR (2004) Surveillance, epidemiology, and end results analysis of 2677 cases of uterine sarcoma 1989–1999. Gynecol Oncol 93:204–208 CrossRef Brooks SE, Zhan M, Cote T, Baquet CR (2004) Surveillance, epidemiology, and end results analysis of 2677 cases of uterine sarcoma 1989–1999. Gynecol Oncol 93:204–208 CrossRef
Zurück zum Zitat Burns B, Curry RH, Bell ME (1979) Morphologic features of prognostic significance in uterine smooth muscle tumors: a review of eighty-four cases. Am J Obstet Gynecol 135:109–114 PubMed Burns B, Curry RH, Bell ME (1979) Morphologic features of prognostic significance in uterine smooth muscle tumors: a review of eighty-four cases. Am J Obstet Gynecol 135:109–114 PubMed
Zurück zum Zitat Chang KL, Crabtree GS et al (1990) Primary uterine endometrial stromal neoplasms. A clinicopathologic study of 117 cases. Am J Surg Pathol 14:415–438 CrossRef Chang KL, Crabtree GS et al (1990) Primary uterine endometrial stromal neoplasms. A clinicopathologic study of 117 cases. Am J Surg Pathol 14:415–438 CrossRef
Zurück zum Zitat Evans HL, Chawla SP, Simpson C, Finn KP (1998) Smooth muscle neoplasms of the uterus other than ordinary leiomyomas. A study of 46 cases, with emphasis on diagnostic criteria and prognostic factors. Cancer 62(10):2239–2247 CrossRef Evans HL, Chawla SP, Simpson C, Finn KP (1998) Smooth muscle neoplasms of the uterus other than ordinary leiomyomas. A study of 46 cases, with emphasis on diagnostic criteria and prognostic factors. Cancer 62(10):2239–2247 CrossRef
Zurück zum Zitat Gadducci A, Sartori E, Landoni F, Zola P, Maggino T, Urgesi A, Lissoni A, Losa G, Fanucchi A (1996) Endometrial stromal sarcoma: analysis of treatment failures and survival. Gynecol Oncol 63:247–253 CrossRef Gadducci A, Sartori E, Landoni F, Zola P, Maggino T, Urgesi A, Lissoni A, Losa G, Fanucchi A (1996) Endometrial stromal sarcoma: analysis of treatment failures and survival. Gynecol Oncol 63:247–253 CrossRef
Zurück zum Zitat Giuntoli RL 2nd, Metzinger DS, DiMarco CS, Cha SS, Sloan JA, Keeney GL, Gostout BS (2003) Retrospective review of 208 patients with leiomyosarcoma of the uterus: prognostic indicators, surgical management, and adjuvant therapy. Gynecol Oncol 89:460–469 CrossRef Giuntoli RL 2nd, Metzinger DS, DiMarco CS, Cha SS, Sloan JA, Keeney GL, Gostout BS (2003) Retrospective review of 208 patients with leiomyosarcoma of the uterus: prognostic indicators, surgical management, and adjuvant therapy. Gynecol Oncol 89:460–469 CrossRef
Zurück zum Zitat Hardman MP, Roman JJ, Burnett AF, Santin AD (2007) Metastatic uterine leiomyosarcoma regression using an aromatase inhibitor. Obstet Gynecol 110:518–520 CrossRef Hardman MP, Roman JJ, Burnett AF, Santin AD (2007) Metastatic uterine leiomyosarcoma regression using an aromatase inhibitor. Obstet Gynecol 110:518–520 CrossRef
Zurück zum Zitat Leitao MM, Soslow RA, Nonaka D, Olshen AB, Aghajanian C, Sabbatini P, Dupont J, Hensley M, Sonoda Y, Barakat RR, Anderson S (2004) Tissue microarray immunohistochemical expression of estrogen, progesterone, and androgen receptors in uterine leiomyomata and leiomyosarcoma. Cancer 101:1455–1462 CrossRef Leitao MM, Soslow RA, Nonaka D, Olshen AB, Aghajanian C, Sabbatini P, Dupont J, Hensley M, Sonoda Y, Barakat RR, Anderson S (2004) Tissue microarray immunohistochemical expression of estrogen, progesterone, and androgen receptors in uterine leiomyomata and leiomyosarcoma. Cancer 101:1455–1462 CrossRef
Zurück zum Zitat Leunen M, Breugelmans M, De Sutter P, Bourgain C, Amy J (2004) Low-grade endometrial stromal sarcoma treated with the aromatase inhibitor letrozole. Gynecol Oncol 95:769–771 CrossRef Leunen M, Breugelmans M, De Sutter P, Bourgain C, Amy J (2004) Low-grade endometrial stromal sarcoma treated with the aromatase inhibitor letrozole. Gynecol Oncol 95:769–771 CrossRef
Zurück zum Zitat Major FJ, Blessing JA, Silverberg SG, Morrow CP, Creasman WT, Currie JL, Yordan E, Brady MF (1993) Prognostic factors in early-stage uterine sarcoma. A gynecologic oncology group study. Cancer 71:1702–1709 CrossRef Major FJ, Blessing JA, Silverberg SG, Morrow CP, Creasman WT, Currie JL, Yordan E, Brady MF (1993) Prognostic factors in early-stage uterine sarcoma. A gynecologic oncology group study. Cancer 71:1702–1709 CrossRef
Zurück zum Zitat Martin-Broto J, Pousa A, De las Penas R, Del Muro G, Gutierrez A, Martinez-Trufero J et al (2016) Randomized phase II study of trabectedin and doxorubicin compared with doxorubicin alone in first-line treatment in patients with advanced soft-tissue sarcomas: A Spanish group for research on sarcoma study. J Clin Oncol 34:2294–2302 CrossRef Martin-Broto J, Pousa A, De las Penas R, Del Muro G, Gutierrez A, Martinez-Trufero J et al (2016) Randomized phase II study of trabectedin and doxorubicin compared with doxorubicin alone in first-line treatment in patients with advanced soft-tissue sarcomas: A Spanish group for research on sarcoma study. J Clin Oncol 34:2294–2302 CrossRef
Zurück zum Zitat Parker WH, Fu YS, Berek JS (1994) Uterine sarcoma in patients operated on for presumed leiomyoma and rapidly growing leiomyoma. Obstet Gynecol 83:414–418 PubMed Parker WH, Fu YS, Berek JS (1994) Uterine sarcoma in patients operated on for presumed leiomyoma and rapidly growing leiomyoma. Obstet Gynecol 83:414–418 PubMed
Zurück zum Zitat Reed NS, Mangioni C, Malmstrom H et al (2008) Phase III randomised study to evaluate the role of adjuvant pelvic radiotherapy in the treatment of uterine sarcomas stages I and II: an EORTC Gynaecological Cancer Group study (protocol 55874). Eur J Cancer 44:808–818 CrossRef Reed NS, Mangioni C, Malmstrom H et al (2008) Phase III randomised study to evaluate the role of adjuvant pelvic radiotherapy in the treatment of uterine sarcomas stages I and II: an EORTC Gynaecological Cancer Group study (protocol 55874). Eur J Cancer 44:808–818 CrossRef
Zurück zum Zitat Reich O, Regauer S, Urdl W, Lahousen M, Winter R (2000) Expression of estrogen and progesterone receptors in low-grade endometrial stromal sarcomas. Br J Cancer 82:1030–1034 CrossRef Reich O, Regauer S, Urdl W, Lahousen M, Winter R (2000) Expression of estrogen and progesterone receptors in low-grade endometrial stromal sarcomas. Br J Cancer 82:1030–1034 CrossRef
Zurück zum Zitat Sutton G, Blessing JA, Malfetano JH (1996a) Ifosfamide and doxorubicin in the treatment of advanced leiomyosarcomas of the uterus: a Gynecologic Oncology Group study. Gynecol Oncol 62:226–229 CrossRef Sutton G, Blessing JA, Malfetano JH (1996a) Ifosfamide and doxorubicin in the treatment of advanced leiomyosarcomas of the uterus: a Gynecologic Oncology Group study. Gynecol Oncol 62:226–229 CrossRef
Zurück zum Zitat Tap W, Jones R, Van Tine B, Chmielowski B, Elias A, Adkins D et al (2016) Olaratumab and doxorubicin versus doxorubicin alone for treatment of soft-tissue sarcoma: An open-label phase 1b and randomised phase 2 trial. Lancet 388:488–497 CrossRef Tap W, Jones R, Van Tine B, Chmielowski B, Elias A, Adkins D et al (2016) Olaratumab and doxorubicin versus doxorubicin alone for treatment of soft-tissue sarcoma: An open-label phase 1b and randomised phase 2 trial. Lancet 388:488–497 CrossRef
Zurück zum Zitat Van der Graaf W, Blay JY, Chawla S, Kim D, Nguyen B, Casali P et al (2012) Pazopanib for metastatic soft-tissue sarcoma (PALETTE): a randomised, double-blind, placebo-controlled phase 3 trial. Lancet 379:1879–1886 CrossRef Van der Graaf W, Blay JY, Chawla S, Kim D, Nguyen B, Casali P et al (2012) Pazopanib for metastatic soft-tissue sarcoma (PALETTE): a randomised, double-blind, placebo-controlled phase 3 trial. Lancet 379:1879–1886 CrossRef
Zurück zum Zitat Weitmann HD, Knocke TH, Kucera H, Potter R (2001) Radiation therapy in the treatment of endometrial stromal sarcoma. Int J Radiat Oncol Biol Phys 49:739–748 CrossRef Weitmann HD, Knocke TH, Kucera H, Potter R (2001) Radiation therapy in the treatment of endometrial stromal sarcoma. Int J Radiat Oncol Biol Phys 49:739–748 CrossRef
Zurück zum Zitat Chan JK, Kawar NM et al (2008) Endometrial stromal sarcoma: a population-based analysis. Br J Cancer 99:1210–1215 CrossRef Chan JK, Kawar NM et al (2008) Endometrial stromal sarcoma: a population-based analysis. Br J Cancer 99:1210–1215 CrossRef
Zurück zum Zitat D’Angelo E, Prat J (2010) Uterine sarcomas: a review. Gynecol Oncol 116(1):131–139 CrossRef D’Angelo E, Prat J (2010) Uterine sarcomas: a review. Gynecol Oncol 116(1):131–139 CrossRef
Zurück zum Zitat Demetri GD, Chawla SP, von Mehren M et al (2009) Efficacy and safety of trabectedin in patients with advanced and metastastic liposarcoma or leiomyosarcoma after failure of prior anthracyclines and ifosfamide: results of a randomized phase II study of two different schedules. J Clin Oncol 27:4188–4196 CrossRef Demetri GD, Chawla SP, von Mehren M et al (2009) Efficacy and safety of trabectedin in patients with advanced and metastastic liposarcoma or leiomyosarcoma after failure of prior anthracyclines and ifosfamide: results of a randomized phase II study of two different schedules. J Clin Oncol 27:4188–4196 CrossRef
Zurück zum Zitat Ducimetière F, Lurkin A et al (2011) Incidence of sarcoma histotypes and molecular subtypes in a prospective epidemiological study with central pathology review and molecular testing. PLoS One 6(8):e20294 CrossRef Ducimetière F, Lurkin A et al (2011) Incidence of sarcoma histotypes and molecular subtypes in a prospective epidemiological study with central pathology review and molecular testing. PLoS One 6(8):e20294 CrossRef
Zurück zum Zitat FIGO committee on Gynecologic Oncology (2009) FIGO staging for uterine sarcomas. Int J Gynecol Obstet 104:179 CrossRef FIGO committee on Gynecologic Oncology (2009) FIGO staging for uterine sarcomas. Int J Gynecol Obstet 104:179 CrossRef
Zurück zum Zitat Gadducci A, Cosio S et al (2008) The management of patients with uterine sarcoma: a debated clinical challenge. Crit Rev Oncol Hematol 65:129–142 CrossRef Gadducci A, Cosio S et al (2008) The management of patients with uterine sarcoma: a debated clinical challenge. Crit Rev Oncol Hematol 65:129–142 CrossRef
Zurück zum Zitat Garg G, Shah JP et al (2010) Stage IA vs. IB endometrial stromal sarcoma: does the new staging system predict survival? Gynecol Oncol 118:8–13 CrossRef Garg G, Shah JP et al (2010) Stage IA vs. IB endometrial stromal sarcoma: does the new staging system predict survival? Gynecol Oncol 118:8–13 CrossRef
Zurück zum Zitat Goff BA, Rice LW, Fleischhacker D, Muntz HG, Falkenberry SS, Nikrui N, Fuller AF Jr (1993) Uterine leiomyosarcoma and endometrial stromal sarcoma: lymph node metastases and sites of recurrence. Gynecol Oncol Jul;50(1):105–109 CrossRef Goff BA, Rice LW, Fleischhacker D, Muntz HG, Falkenberry SS, Nikrui N, Fuller AF Jr (1993) Uterine leiomyosarcoma and endometrial stromal sarcoma: lymph node metastases and sites of recurrence. Gynecol Oncol Jul;50(1):105–109 CrossRef
Zurück zum Zitat Hensley ML, Maki R, Venkatraman E, Geller G, Lovegren M, Aghajanian C, Sabbatini P, Tong W, Barakat R, Spriggs DR (2002) Gemcitabine and docetaxel in patients with unresectable leiomyosarcoma: results of a phase II trial. J Clin Oncol 20:2824–2831 CrossRef Hensley ML, Maki R, Venkatraman E, Geller G, Lovegren M, Aghajanian C, Sabbatini P, Tong W, Barakat R, Spriggs DR (2002) Gemcitabine and docetaxel in patients with unresectable leiomyosarcoma: results of a phase II trial. J Clin Oncol 20:2824–2831 CrossRef
Zurück zum Zitat Hensley ML et al (2009) „Adjuvant gemcitabine plus docetaxel for completely resected stages I-IV high grade uterine leiomyosarcoma: results of a prospective study.“ Gynecol Oncol 112(3):563–567 CrossRef Hensley ML et al (2009) „Adjuvant gemcitabine plus docetaxel for completely resected stages I-IV high grade uterine leiomyosarcoma: results of a prospective study.“ Gynecol Oncol 112(3):563–567 CrossRef
Zurück zum Zitat Hensley ML et al (2013) „Adjuvant therapy for high-grade, uterine-limited leiomyosarcoma: results of a phase 2 trial (SARC 005)“. Cancer 119(8):1555–1561 CrossRef Hensley ML et al (2013) „Adjuvant therapy for high-grade, uterine-limited leiomyosarcoma: results of a phase 2 trial (SARC 005)“. Cancer 119(8):1555–1561 CrossRef
Zurück zum Zitat Jones MW, Norris HJ (1995) Clinicopathologic study of 28 uterine leiomyosarcomas with metastasis. Int J Gynecol Pathol 14(3):243–249 CrossRef Jones MW, Norris HJ (1995) Clinicopathologic study of 28 uterine leiomyosarcomas with metastasis. Int J Gynecol Pathol 14(3):243–249 CrossRef
Zurück zum Zitat Kurihara S, Oda Y et al (2008) Endometrial stromal sarcomas and related high-grade sarcomas: immunohistochemical and molecular genetic study of 31 cases. Am J Surg Pathol 32:1228–1238 CrossRef Kurihara S, Oda Y et al (2008) Endometrial stromal sarcomas and related high-grade sarcomas: immunohistochemical and molecular genetic study of 31 cases. Am J Surg Pathol 32:1228–1238 CrossRef
Zurück zum Zitat Leitao MM, Sonoda Y, Brennan MF, Barakat RR, Chi DS (2003) Incidence of lymph node and ovarian metastases in leiomyosarcoma of the uterus. Gynecol Oncol 91:209–212 CrossRef Leitao MM, Sonoda Y, Brennan MF, Barakat RR, Chi DS (2003) Incidence of lymph node and ovarian metastases in leiomyosarcoma of the uterus. Gynecol Oncol 91:209–212 CrossRef
Zurück zum Zitat Lissoni A, Cormio G, Perego P, Gabriele A, Cantu MG, Bratina G (1997) Conservative management of endometrial stromal sarcoma in young women. Int J Gynecol Cancer 7:364–367 CrossRef Lissoni A, Cormio G, Perego P, Gabriele A, Cantu MG, Bratina G (1997) Conservative management of endometrial stromal sarcoma in young women. Int J Gynecol Cancer 7:364–367 CrossRef
Zurück zum Zitat Li N, Wu LY, Zhang HT, An JS, Li XG, Ma SK (2008) Treatment options in stage I endometrial stromal sarcoma: a retrospective analysis of 53 cases. Gynecol Oncol 108(2):306–311 CrossRef Li N, Wu LY, Zhang HT, An JS, Li XG, Ma SK (2008) Treatment options in stage I endometrial stromal sarcoma: a retrospective analysis of 53 cases. Gynecol Oncol 108(2):306–311 CrossRef
Zurück zum Zitat Leath CA 3rd, Huh WK et al (2007) A multi-institutional review of outcomes of endometrial stromal sarcoma. Gynecol Oncol 105:630–634 CrossRef Leath CA 3rd, Huh WK et al (2007) A multi-institutional review of outcomes of endometrial stromal sarcoma. Gynecol Oncol 105:630–634 CrossRef
Zurück zum Zitat Lee CH, Ou WB, Marino-Enriquez A et al (2012) 14-3-3 fusion oncogene in high-grade endometrial stromal sarcoma. Proc natl Acad Sci USA 109:929–934 CrossRef Lee CH, Ou WB, Marino-Enriquez A et al (2012) 14-3-3 fusion oncogene in high-grade endometrial stromal sarcoma. Proc natl Acad Sci USA 109:929–934 CrossRef
Zurück zum Zitat Mahdavi A, Monk BJ, Ragazzo J, Hunter MI, Lentz SE, Vasilev SA, Tewari KS (2009) Pelvic radiation improves local control after hysterectomy for uterine leiomyosarcoma: a 20-year experience. Int J Gynecol Cancer 19(6):1080–1084 CrossRef Mahdavi A, Monk BJ, Ragazzo J, Hunter MI, Lentz SE, Vasilev SA, Tewari KS (2009) Pelvic radiation improves local control after hysterectomy for uterine leiomyosarcoma: a 20-year experience. Int J Gynecol Cancer 19(6):1080–1084 CrossRef
Zurück zum Zitat Malouf GG, Duclos J et al (2010) Impact of adjuvant treatment modalities on the management of patients with stages I-II endometrial stromal sarcoma. Ann Oncol 21:2102–2106 CrossRef Malouf GG, Duclos J et al (2010) Impact of adjuvant treatment modalities on the management of patients with stages I-II endometrial stromal sarcoma. Ann Oncol 21:2102–2106 CrossRef
Zurück zum Zitat Muss HB, Bundy BN, DISaia PJ, Homesley HD, Fowler WC, Creasman W, Yordan E (1985) Treatment of recurrent or advanced uterine sarcoma: a randomized trial of doxorubicin versus doxorubicin and cyclophosphamide: a phase III trial of the Gynecologic Oncology Group. Cancer 55:1648–1653 CrossRef Muss HB, Bundy BN, DISaia PJ, Homesley HD, Fowler WC, Creasman W, Yordan E (1985) Treatment of recurrent or advanced uterine sarcoma: a randomized trial of doxorubicin versus doxorubicin and cyclophosphamide: a phase III trial of the Gynecologic Oncology Group. Cancer 55:1648–1653 CrossRef
Zurück zum Zitat Nordal RN, Kjorstad KE, Stenwig AE, Trope CG (1993) Leiomyosarcoma and endometrial stromal sarcoma of the uterus. A survey of patients treated in the Norwegian Radium Hospital 1976–1985. Int J Gynecol Cancer 3:110–115 CrossRef Nordal RN, Kjorstad KE, Stenwig AE, Trope CG (1993) Leiomyosarcoma and endometrial stromal sarcoma of the uterus. A survey of patients treated in the Norwegian Radium Hospital 1976–1985. Int J Gynecol Cancer 3:110–115 CrossRef
Zurück zum Zitat Okuno S, Edmonson J, Mahoney M, Buckner JC, Frytak S, Galanis E (2002) Phase II trial of gemcitabine in advanced sarcomas. Cancer 94:3225–3229 CrossRef Okuno S, Edmonson J, Mahoney M, Buckner JC, Frytak S, Galanis E (2002) Phase II trial of gemcitabine in advanced sarcomas. Cancer 94:3225–3229 CrossRef
Zurück zum Zitat Omura GA, Major FJ, Blessing JA, Sedlacek TV, Thigpen JT, Creasman WT, Zaino RT (1983) A randomized study of adriamycin with and without dimethyl triazenoimidazole carboxamide in advanced uterine sarcomas. Cancer 52:626–632 CrossRef Omura GA, Major FJ, Blessing JA, Sedlacek TV, Thigpen JT, Creasman WT, Zaino RT (1983) A randomized study of adriamycin with and without dimethyl triazenoimidazole carboxamide in advanced uterine sarcomas. Cancer 52:626–632 CrossRef
Zurück zum Zitat Omura GA, Blessing JA, Major FA (1985) A randomized clinical trial of adjuvant adriamycin in uterine sarcomas: a gynecologic oncology group study. J Clin Oncol 3:1240–1245 CrossRef Omura GA, Blessing JA, Major FA (1985) A randomized clinical trial of adjuvant adriamycin in uterine sarcomas: a gynecologic oncology group study. J Clin Oncol 3:1240–1245 CrossRef
Zurück zum Zitat Pautier P, Genestie C et al (2000) Analysis of clinicopathologic prognostic factors for 157 uterine sarcomas and evaluation of a grading score validated for soft tissue sarcoma. Cancer 88:1425–1431 CrossRef Pautier P, Genestie C et al (2000) Analysis of clinicopathologic prognostic factors for 157 uterine sarcomas and evaluation of a grading score validated for soft tissue sarcoma. Cancer 88:1425–1431 CrossRef
Zurück zum Zitat Pautier P, Floquet A et al (2012) A randomized clinical trial of adjuvant chemotherapy with doxorubicin, ifosfamide, and cisplatin followed by radiotherapy versus radiotherapy alone in patients with localized uterine sarcomas (SARCGYN study) A study of the French Sarcoma Group. Ann Oncol 24:1099–1104 CrossRef Pautier P, Floquet A et al (2012) A randomized clinical trial of adjuvant chemotherapy with doxorubicin, ifosfamide, and cisplatin followed by radiotherapy versus radiotherapy alone in patients with localized uterine sarcomas (SARCGYN study) A study of the French Sarcoma Group. Ann Oncol 24:1099–1104 CrossRef
Zurück zum Zitat Peters WA 3rd, Howard DR, Andersen WA, Figge DC (1994) Uterine smooth-muscle tumors of uncertain malignant potential. Obstet Gynecol 83:1015–1020 CrossRef Peters WA 3rd, Howard DR, Andersen WA, Figge DC (1994) Uterine smooth-muscle tumors of uncertain malignant potential. Obstet Gynecol 83:1015–1020 CrossRef
Zurück zum Zitat Petru E, Lück HJ, Stuart G, Gaffney D, Millan D, Vergote I (2009) Gynecologic Cancer Intergroup (GCIG) proposals for changes of the current FIGO staging system. Eur J Obstet Gynecol Reprod Biol 143:69–74 CrossRef Petru E, Lück HJ, Stuart G, Gaffney D, Millan D, Vergote I (2009) Gynecologic Cancer Intergroup (GCIG) proposals for changes of the current FIGO staging system. Eur J Obstet Gynecol Reprod Biol 143:69–74 CrossRef
Zurück zum Zitat Riopel J, Plante M, Renaud M-C, Roy M, Têtu B (2005) Lymph node metastases in low-grade endometrial stromal sarcoma. Gynecol Oncol 96:402–406 CrossRef Riopel J, Plante M, Renaud M-C, Roy M, Têtu B (2005) Lymph node metastases in low-grade endometrial stromal sarcoma. Gynecol Oncol 96:402–406 CrossRef
Zurück zum Zitat Sanfilippo R, Grosso F, Jones RL et al (2011) Trabectedin in advanced uterine leiomyosarcomas: A retrospective case series analysis from two reference centers. Gynecol Oncol Sep 12 Sanfilippo R, Grosso F, Jones RL et al (2011) Trabectedin in advanced uterine leiomyosarcomas: A retrospective case series analysis from two reference centers. Gynecol Oncol Sep 12
Zurück zum Zitat Sutton GP, Blessing JA, Barrett RJ, McGehee R (1992) Phase II trial of ifosfamide and mesna in leiomyosarcoma of the uterus: a gynecologic oncology group study. Am J Obstet Gynecol 166:556–559 CrossRef Sutton GP, Blessing JA, Barrett RJ, McGehee R (1992) Phase II trial of ifosfamide and mesna in leiomyosarcoma of the uterus: a gynecologic oncology group study. Am J Obstet Gynecol 166:556–559 CrossRef
Zurück zum Zitat Sutton G, Blessing JA, Park R, DiSaia PJ, Rosenshein N (1996b) Ifosfamide treatment of recurrent or metastatic endometrial stromal sarcomas previously unexposed to chemotherapy: a study of the gynecologic oncology group. Obstet Gynecol 87:747–750 CrossRef Sutton G, Blessing JA, Park R, DiSaia PJ, Rosenshein N (1996b) Ifosfamide treatment of recurrent or metastatic endometrial stromal sarcomas previously unexposed to chemotherapy: a study of the gynecologic oncology group. Obstet Gynecol 87:747–750 CrossRef
Zurück zum Zitat Tanner EJ, Garg K et al (2012) High grade undifferentiated uterine sarcoma: surgery, treatment, and survival outcomes. Gynecol Oncol 127:27–31 CrossRef Tanner EJ, Garg K et al (2012) High grade undifferentiated uterine sarcoma: surgery, treatment, and survival outcomes. Gynecol Oncol 127:27–31 CrossRef
Zurück zum Zitat Wade K, Quinn MA, Hammond I, Williams K, Cauchi M (1990) Uterine sarcoma: steroid receptors and response to hormonal therapy. Gynecol Oncol 39:364–367 CrossRef Wade K, Quinn MA, Hammond I, Williams K, Cauchi M (1990) Uterine sarcoma: steroid receptors and response to hormonal therapy. Gynecol Oncol 39:364–367 CrossRef
Metadaten
Titel
Maligne, nichtepitheliale Tumoren des Corpus uteri (ausschließlich des Karzinosarkoms)
verfasst von
Patrick Imesch
Edgar Petru
Daniel Fink
Copyright-Jahr
2019
Verlag
Springer Berlin Heidelberg
DOI
https://doi.org/10.1007/978-3-662-57430-0_4

Passend zum Thema

DKK 2024
21. - 24. Februar 2024 | Berlin

Kongressdossier zum Deutschen Krebskongress 2024

Auf dieser Seite werden wir Sie mit tagesaktuellen Berichten vom Deutschen Krebskongress auf dem Laufenden halten. Vor dem Start des Kongresses finden Sie hier zudem Ausblicke auf spannende Themen. Expertinnen und Experten erzählen, auf welche DKK-Sessions sie sich besonders freuen.

In Kooperation mit:
Deutsche Krebsgesellschaft e. V. und Stiftung Deutsche Krebshilfe

Passend zum Thema

ANZEIGE

Finale OS-Analyse der MONARCH-3-Studie vorgestellt

In der MONARCH-3-Studie erhielten Patientinnen mit fortgeschrittenem HR+, HER2- Brustkrebs Abemaciclib [1,a] in Kombination mit nicht-steroidalem Aromatasehemmer (nsAI). Die finalen Daten bestätigen den in früheren Analysen beobachteten Unterschied zugunsten der Kombinationstherapie. [2] Details dazu vom SABCS 2023.

ANZEIGE

Neue 5-Jahres-Daten der monarchE Studie zur adjuvanten Brustkrebstherapie

Abemaciclib [1,a] ist in Kombination mit einer endokrinen Therapie (ET) zur adjuvanten Behandlung des HR+, HER2- Mammakarzinoms mit hohem Rezidivrisiko# indiziert. Auf dem ESMO 2023 wurden nun neue Follow-Up Daten der Zulassungsstudie vorgestellt, die einen klaren Vorteil der Kombination gegenüber der alleinigen ET auch nach 5 Jahren aufzeigen. [2,3]

ANZEIGE

Die Bedeutung der CDK4 & 6 Inhibition beim HR+, HER2- Mammakarzinom

Es erwarten Sie praxisrelevante Patientenfälle, kompakte Studiendarstellungen, informative Experteninterviews sowie weitere spannende Inhalte rund um das HR+, HER2- Mammakarzinom. 
 

Passend zum Thema

ANZEIGE

Im Dialog mit jungen Dermatologen: Wund- und Narbenversorgung in der Praxis

Dr. med. Max Tischler gab auf dem Spektrum Dermatologie Kongress 2.0 seine Sicht als junger Dermatologe auf die Kongressinhalte und ordnete die Erkenntnisse der verschiedenen Vorträge in den täglichen Praxisalltag ein.

ANZEIGE

Wie verhindert man die Progression aktinischer Keratosen?

Aktuelle Optionen zur Therapie aktinischer Keratosen stellte Prof. Dr. Eggert Stockfleth beim Kongress Spektrum Dermatologie 2.0 vor. Beispielsweise die laserunterstützte photodynamische Therapie. Außerdem rief er wegen des unklaren Progressionsrisikos zu einer adäquaten Behandlung von mehr Menschen mit aktinischer Keratose auf.

ANZEIGE

Bepanthen® unterstützt bei vielen Indikationen die Regeneration der Haut

Content Hub

Bepanthen® Wund- und Heilsalbe wird heute wie bei der Einführung vor 70 Jahren erfolgreich bei kleinen Alltagsverletzungen eingesetzt. Moderne Forschung – Untersuchungen an Hautmodellen, Genexpressionsanalysen und klinische Studien – schafft darüber hinaus Evidenz für neue Anwendungsgebiete. So kann die Dexpanthenol-haltige Salbe heute z.B. zur Nachbehandlung einer Lasertherapie bei aktinischer Keratose oder Tattoo-Entfernung eingesetzt werden. Erfahren Sie hier mehr über moderne Forschung zu Bepanthen.